LIVIVO - Search results -

Search results

Result 1 - 10 of total 101

Search options

Article ; Online: Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer.

Hálfdánarson, Óskar Ö / Pottegård, Anton / Lund, Sigrún H / Ogmundsdottir, Margret H / Ogmundsdottir, Helga M / Zoega, Helga

Basic & clinical pharmacology & toxicology

2020 Volume 126, Issue 6, Page(s) 484–491

Abstract: Proton pump inhibitors (PPIs) are commonly used drugs among cancer patients. Due to conflicting reports on their safety, we aimed to determine whether PPI use is associated with mortality among prostate cancer patients. In this population-based cohort ... ...

Abstract	Proton pump inhibitors (PPIs) are commonly used drugs among cancer patients. Due to conflicting reports on their safety, we aimed to determine whether PPI use is associated with mortality among prostate cancer patients. In this population-based cohort study, we identified incident diagnoses of prostate cancer between 2007 and 2012 (n = 1058). Follow-up was from 12 months after diagnosis until death, emigration or end the of study. Post-diagnosis use was defined as ≥2 filled prescriptions following diagnosis. We used time-dependent Cox proportional hazard regression models to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate cancer-specific and all-cause mortality associated with post-diagnosis use of PPIs. We identified 347 (32.8%) post-diagnosis PPI users and 711 (67.2%) non-users after diagnosis. Of the 347 patients using PPIs after diagnosis, 59 (17.0%) died due to any cause and 22 (6.3%) due to prostate cancer, compared with 144 (20.3%) and 76 (10.7%) among non-users after diagnosis, respectively. Post-diagnosis PPI use was not associated with prostate cancer-specific mortality (HR 0.88; 95% CI: 0.52-1.48) or all-cause mortality (HR 1.02; 95% CI: 0.73-1.43). Contrary to a previous report, this study did not find evidence of an association between post-diagnosis PPI use and mortality among prostate cancer patients.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Humans ; Iceland/epidemiology ; Male ; Middle Aged ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/mortality ; Proton Pump Inhibitors/administration & dosage ; Proton Pump Inhibitors/adverse effects ; Risk Factors
Chemical Substances	Proton Pump Inhibitors
Language	English
Publishing date	2020-01-08
Publishing country	England
Document type	Journal Article
ZDB-ID	2134679-3
ISSN	1742-7843 ; 1742-7835
ISSN (online)	1742-7843
ISSN	1742-7835
DOI	10.1111/bcpt.13379
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.144: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Effect of a Lifestyle-Focused Web-Based Application on Risk Factor Management in Patients Who Have Had a Myocardial Infarction: Randomized Controlled Trial.

Ögmundsdóttir Michelsen, Halldóra / Sjölin, Ingela / Bäck, Maria / Gonzalez Garcia, Manuel / Olsson, Anneli / Sandberg, Camilla / Schiopu, Alexandru / Leósdóttir, Margrét

Journal of medical Internet research

2022 Volume 24, Issue 3, Page(s) e25224

Abstract: Background: Cardiac rehabilitation is central in reducing mortality and morbidity after myocardial infarction. However, the fulfillment of guideline-recommended cardiac rehabilitation targets is unsatisfactory. eHealth offers new possibilities to ... ...

Abstract	Background: Cardiac rehabilitation is central in reducing mortality and morbidity after myocardial infarction. However, the fulfillment of guideline-recommended cardiac rehabilitation targets is unsatisfactory. eHealth offers new possibilities to improve clinical care. Objective: This study aims to assess the effect of a web-based application designed to support adherence to lifestyle advice and self-control of risk factors (intervention) in addition to center-based cardiac rehabilitation, compared with cardiac rehabilitation only (usual care). Methods: All 150 patients participated in cardiac rehabilitation. Patients randomized to the intervention group (n=101) received access to the application for 25 weeks where information about lifestyle (eg, diet and physical activity), risk factors (eg, weight and blood pressure [BP]), and symptoms could be registered. The software provided feedback and lifestyle advice. The primary outcome was a change in submaximal exercise capacity (Watts [W]) between follow-up visits. Secondary outcomes included changes in modifiable risk factors between baseline and follow-up visits and uptake and adherence to the application. Regression analysis was used, adjusting for relevant baseline variables. Results: There was a nonsignificant trend toward a larger change in exercise capacity in the intervention group (n=66) compared with the usual care group (n=40; +14.4, SD 19.0 W, vs +10.3, SD 16.1 W; P=.22). Patients in the intervention group achieved significantly larger BP reduction compared with usual care patients at 2 weeks (systolic -27.7 vs -16.4 mm Hg; P=.006) and at 6 to 10 weeks (systolic -25.3 vs -16.4 mm Hg; P=.02, and diastolic -13.4 vs -9.1 mm Hg; P=.05). A healthy diet index score improved significantly more between baseline and the 2-week follow-up in the intervention group (+2.3 vs +1.4 points; P=.05), mostly owing to an increase in the consumption of fish and fruit. At 6 to 10 weeks, 64% (14/22) versus 46% (5/11) of smokers in the intervention versus usual care groups had quit smoking, and at 12 to 14 months, the respective percentages were 55% (12/22) versus 36% (4/11). However, the number of smokers in the study was low (33/149, 21.9%), and the differences were nonsignificant. Attendance in cardiac rehabilitation was high, with 96% (96/100) of patients in the intervention group and 98% (48/49) of patients receiving usual care only attending 12- to 14-month follow-up. Uptake (logging data in the application at least once) was 86.1% (87/101). Adherence (logging data at least twice weekly) was 91% (79/87) in week 1 and 56% (49/87) in week 25. Conclusions: Complementing cardiac rehabilitation with a web-based application improved BP and dietary habits during the first months after myocardial infarction. A nonsignificant tendency toward better exercise capacity and higher smoking cessation rates was observed. Although the study group was small, these positive trends support further development of eHealth in cardiac rehabilitation. Trial registration: ClinicalTrials.gov NCT03260582; https://clinicaltrials.gov/ct2/show/NCT03260582. International registered report identifier (irrid): RR2-10.1186/s13063-018-3118-1.
MeSH term(s)	Humans ; Internet ; Life Style ; Myocardial Infarction/therapy ; Quality of Life ; Risk Factors ; Software
Language	English
Publishing date	2022-03-31
Publishing country	Canada
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2028830-X
ISSN	1438-8871 ; 1439-4456
ISSN (online)	1438-8871
ISSN	1439-4456
DOI	10.2196/25224
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cytotoxic effects of halogenated tin phosphinoyldithioformate complexes against several cancer cell lines.

Balogová, Michaela / Sharma, Shubham / Cherek, Paulina / Ólafsson, Sigurjón N / Jónsdóttir, Sigrídur / Ögmundsdóttir, Helga M / Damodaran, Krishna K

Dalton transactions (Cambridge, England : 2003)

2022 Volume 51, Issue 34, Page(s) 13119–13128

Abstract: ... We report two monoorganotin(IV) complexes based on a dibenzyl phosphinoyldithioformate (H-DBPTF) ligand ...

Abstract	Organotin complexes are studied as promising alternatives to the anticancer drug cisplatin. We report two monoorganotin(IV) complexes based on a dibenzyl phosphinoyldithioformate (H-DBPTF) ligand, containing either bromide (Sn-DBPTF-1) or chloride (Sn-DBPTF-2) anions. The complexes were characterized by standard analytical techniques and the structural details of these complexes were elucidated by single crystal X-ray diffraction. Sn-DBPTF-1 was cytotoxic at IC
MeSH term(s)	Female ; Humans ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Apoptosis ; Cell Line, Tumor ; Drug Screening Assays, Antitumor ; Ovarian Neoplasms ; Tin/pharmacology
Chemical Substances	Antineoplastic Agents ; Tin (7440-31-5)
Language	English
Publishing date	2022-08-30
Publishing country	England
Document type	Journal Article
ZDB-ID	1472887-4
ISSN	1477-9234 ; 1364-5447 ; 0300-9246 ; 1477-9226
ISSN (online)	1477-9234 ; 1364-5447
ISSN	0300-9246 ; 1477-9226
DOI	10.1039/d2dt01127a
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: ATG7(2) Interacts With Metabolic Proteins and Regulates Central Energy Metabolism.

Ostacolo, Kevin / López García de Lomana, Adrián / Larat, Clémence / Hjaltalin, Valgerdur / Holm, Kristrun Yr / Hlynsdóttir, Sigríður S / Soucheray, Margaret / Sooman, Linda / Rolfsson, Ottar / Krogan, Nevan J / Steingrimsson, Eirikur / Swaney, Danielle L / Ogmundsdottir, Margret H

Traffic (Copenhagen, Denmark)

2024 Volume 25, Issue 4, Page(s) e12933

Abstract: Macroautophagy/autophagy is an essential catabolic process that targets a wide variety of cellular components including proteins, organelles, and pathogens. ATG7, a protein involved in the autophagy process, plays a crucial role in maintaining cellular ... ...

Abstract	Macroautophagy/autophagy is an essential catabolic process that targets a wide variety of cellular components including proteins, organelles, and pathogens. ATG7, a protein involved in the autophagy process, plays a crucial role in maintaining cellular homeostasis and can contribute to the development of diseases such as cancer. ATG7 initiates autophagy by facilitating the lipidation of the ATG8 proteins in the growing autophagosome membrane. The noncanonical isoform ATG7(2) is unable to perform ATG8 lipidation; however, its cellular regulation and function are unknown. Here, we uncovered a distinct regulation and function of ATG7(2) in contrast with ATG7(1), the canonical isoform. First, affinity-purification mass spectrometry analysis revealed that ATG7(2) establishes direct protein-protein interactions (PPIs) with metabolic proteins, whereas ATG7(1) primarily interacts with autophagy machinery proteins. Furthermore, we identified that ATG7(2) mediates a decrease in metabolic activity, highlighting a novel splice-dependent function of this important autophagy protein. Then, we found a divergent expression pattern of ATG7(1) and ATG7(2) across human tissues. Conclusively, our work uncovers the divergent patterns of expression, protein interactions, and function of ATG7(2) in contrast to ATG7(1). These findings suggest a molecular switch between main catabolic processes through isoform-dependent expression of a key autophagy gene.
MeSH term(s)	Humans ; Autophagosomes/metabolism ; Autophagy ; Autophagy-Related Proteins/metabolism ; Energy Metabolism ; Microtubule-Associated Proteins/metabolism ; Protein Isoforms/metabolism
Chemical Substances	Autophagy-Related Proteins ; Microtubule-Associated Proteins ; Protein Isoforms ; ATG7 protein, human (EC 6.2.1.45)
Language	English
Publishing date	2024-04-10
Publishing country	England
Document type	Journal Article
ZDB-ID	1483852-7
ISSN	1600-0854 ; 1398-9219
ISSN (online)	1600-0854
ISSN	1398-9219
DOI	10.1111/tra.12933
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5634: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Tailored nurse-led cardiac rehabilitation after myocardial infarction results in better risk factor control at one year compared to traditional care: a retrospective observational study.

Ögmundsdottir Michelsen, Halldora / Nilsson, Marie / Scherstén, Fredrik / Sjölin, Ingela / Schiopu, Alexandru / Leosdottir, Margret

BMC cardiovascular disorders

2018 Volume 18, Issue 1, Page(s) 167

Abstract: Background: Cardiac rehabilitation improves prognosis after an acute myocardial infarction (AMI), however, the optimal method of implementation is unknown. The aim of the study was to evaluate the effect of individually-tailored, nurse-led cardiac ... ...

Abstract	Background: Cardiac rehabilitation improves prognosis after an acute myocardial infarction (AMI), however, the optimal method of implementation is unknown. The aim of the study was to evaluate the effect of individually-tailored, nurse-led cardiac rehabilitation on patient outcomes. Method: This single-centre retrospective observational study included 217 patients (62 ± 9 years, 73% men). All patients attended cardiac rehabilitation including at least two follow-up consultations with a nurse. Patients receiving traditional care (n = 105) had a routine cardiologist consultation, while for those receiving tailored care (n = 112) their need for a cardiologist consultation was individually evaluated by the nurses. Regression analysis was used to analyse risk factor control and hospital readmissions at one year. Results: Patients in the tailored group achieved better control of total cholesterol (- 0.1 vs + 0.4 mmol/L change between baseline (time of index event) and 12-14-month follow-up, (p = 0.01), LDL cholesterol (- 0.1 vs + 0.2 mmol/L, p = 0.02) and systolic blood pressure (- 2.1 vs + 4.3 mmHg, p = 0.01). Active smokers, at baseline, were more often smoke-free at one-year in the tailored group [OR 0.32 (0.1-1.0), p = 0.05]. There was a no significant difference in re-admissions during the first year of follow-up. In the tailored group 60% of the patients had a cardiologist consultation compared to 98% in the traditional group (p < 0.001). The number of nurse visits was the same in both groups, while the number of telephone contacts was 38% higher in the tailored group (p = 0.02). Conclusion: A tailored, nurse-led cardiac rehabilitation programme can improve risk factor management in post-AMI patients.
MeSH term(s)	Aged ; Blood Pressure ; Cardiac Rehabilitation/nursing ; Cardiologists ; Exercise ; Female ; Health Status ; Humans ; Lipids/blood ; Male ; Middle Aged ; Myocardial Infarction/diagnosis ; Myocardial Infarction/nursing ; Myocardial Infarction/physiopathology ; Myocardial Infarction/rehabilitation ; Nurse's Role ; Patient Compliance ; Patient Readmission ; Referral and Consultation ; Retrospective Studies ; Risk Factors ; Risk Reduction Behavior ; Smoking Cessation ; Sweden ; Time Factors ; Treatment Outcome ; Weight Loss
Chemical Substances	Lipids
Language	English
Publishing date	2018-08-15
Publishing country	England
Document type	Comparative Study ; Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2059859-2
ISSN	1471-2261 ; 1471-2261
ISSN (online)	1471-2261
ISSN	1471-2261
DOI	10.1186/s12872-018-0907-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Anti-proliferative and pro-apoptotic effects of lichen-derived compound protolichesterinic acid are not mediated by its lipoxygenase-inhibitory activity.

Bessadóttir, M / Eiríksson, F F / Becker, S / Ögmundsdóttir, M H / Ómarsdóttir, S / Thorsteinsdóttir, M / Ögmundsdóttir, H M

Prostaglandins, leukotrienes, and essential fatty acids

2015 Volume 98, Page(s) 39–47

Abstract: Lipoxygenases (LOXs) and their products are involved in several biological functions and have been associated with carcinogenesis. Protolichesterinic acid (PA), a lichen metabolite, inhibits 5- and 12-LOX and has anti-proliferative effects on various ... ...

Abstract	Lipoxygenases (LOXs) and their products are involved in several biological functions and have been associated with carcinogenesis. Protolichesterinic acid (PA), a lichen metabolite, inhibits 5- and 12-LOX and has anti-proliferative effects on various cancer cell lines. Here, PA was shown to inhibit proliferation of multiple myeloma cells, RPMI 8226 and U266, and pancreatic cancer cells AsPC-1. Apoptosis was induced only in multiple myeloma cells. Cell-cycle associated changes in expression and sub-cellular localization of 5- and 12-LOX were not affected by PA but increased cytoplasmic localisation was found to accompany morphological changes at later stages. Assessment by mass spectrometry showed that PA entered the pancreatic cancer cells. However, effects on LOX metabolites were only evident after treatment with concentrations exceeding those having anti-proliferative effects and no effects were measurable in the myeloma cells. We conclude that the anti-proliferative and pro-apoptotic effects of PA are not mediated directly through inhibition of LOX activity.
MeSH term(s)	4-Butyrolactone/analogs & derivatives ; 4-Butyrolactone/pharmacology ; Apoptosis ; Arachidonate 12-Lipoxygenase/metabolism ; Arachidonate 5-Lipoxygenase/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cytoplasm/enzymology ; Dose-Response Relationship, Drug ; Gene Expression Regulation, Enzymologic/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lichens/chemistry ; Multiple Myeloma/drug therapy ; Multiple Myeloma/enzymology ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/enzymology
Chemical Substances	protolichesterinic acid (1448-96-0) ; Arachidonate 12-Lipoxygenase (EC 1.13.11.31) ; ALOX12 protein, human (EC 1.13.11.31.) ; Arachidonate 5-Lipoxygenase (EC 1.13.11.34) ; ALOX5 protein, human (EC 1.3.11.34) ; 4-Butyrolactone (OL659KIY4X)
Language	English
Publishing date	2015-07
Publishing country	Scotland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	286714-x
ISSN	1532-2823 ; 0952-3278
ISSN (online)	1532-2823
ISSN	0952-3278
DOI	10.1016/j.plefa.2015.04.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2123: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immune reaction to breast cancer: for better or for worse?

Ogmundsdóttir, H M

Archivum immunologiae et therapiae experimentalis

2001 Volume 49 Suppl 2, Page(s) S75–81

Abstract: The infiltration of breast carcinomas with lymphoid cells has often been interpreted as an indication of an active immune response against the tumour and, thus, a favourable prognostic sign. Several studies have, however, cast doubt on this assumption. ... ...

Abstract	The infiltration of breast carcinomas with lymphoid cells has often been interpreted as an indication of an active immune response against the tumour and, thus, a favourable prognostic sign. Several studies have, however, cast doubt on this assumption. In situ breast carcinomas are more common than invasive cancers, and it may be speculated that immune surveillance plays a role in preventing some localized cancers from becoming invasive. A secondary type of immune surveillance might be implicated in the long persistence of dormant breast carcinoma cells in the bone marrow. Breast cancer cells can carry tumor-associated antigens, particularly MUC1. These may elicit specific antibody responses, but there is less evidence for a cytotoxic T lymphocyte (CTL) response. There are indications that professional antigen-presenting cells (APC) may be present and active at the edges of breast tumours. Breast cancer cells may also interact directly with macrophages and natural killer (NK) cells. In terms of immune effector mechanisms in breast cancer, the communication with potential effector cells is likely to be often faulty because of altered expression of HLA class I molecules. Pleiotrophic cytokines are frequently present and could have a variety of effects ranging from growth inhibition to stimulated proliferation, loss of cell adhesion and activation of matrix-degrading enzymes. Fas ligand is unlikely to play a role in the immune evasion of breast cancer. There is thus evidence for a variety of immune reactions to breast cancer. It is possible that they mediate some form of surveillance, but growing, invasive tumours have escape routes and may even use cytokines to their advantage.
MeSH term(s)	Breast Neoplasms/immunology ; CD40 Antigens/physiology ; Cytokines/biosynthesis ; Female ; Histocompatibility Antigens Class I/analysis ; Humans ; Monitoring, Immunologic ; Mucin-1/physiology
Chemical Substances	CD40 Antigens ; Cytokines ; Histocompatibility Antigens Class I ; Mucin-1
Language	English
Publishing date	2001
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	282209-x
ISSN	1661-4917 ; 0004-069X
ISSN (online)	1661-4917
ISSN	0004-069X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 393: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of a lifestyle-focused electronic patient support application for improving risk factor management, self-rated health, and prognosis in post-myocardial infarction patients: study protocol for a multi-center randomized controlled trial.

Gonzalez, Manuel / Sjölin, Ingela / Bäck, Maria / Ögmundsdottir Michelsen, Halldora / Tanha, Tina / Sandberg, Camilla / Schiopu, Alexandru / Leosdottir, Margret

Trials

2019 Volume 20, Issue 1, Page(s) 76

Abstract: Background: Cardiac rehabilitation (CR) programs addressing risk factor management, educational interventions, and exercise contribute to reduce mortality after myocardial infarction (MI). However, the fulfillment of guideline-recommended CR targets is ... ...

Abstract	Background: Cardiac rehabilitation (CR) programs addressing risk factor management, educational interventions, and exercise contribute to reduce mortality after myocardial infarction (MI). However, the fulfillment of guideline-recommended CR targets is currently unsatisfactory. eHealth, i.e., the use of electronic communication for healthcare, including the use of mobile smartphone applications combined with different sensors and interactive computerized programs, offers a new array of possibilities to provide clinical care. The present study aims to assess the efficacy of a web-based application (app) designed to support persons in adhering to lifestyle advice and medication as a complement to traditional CR programs for improvement of risk factors and clinical outcomes in patients with MI compared with usual care. Methods/design: An open-label multi-center randomized controlled trial is being conducted at different CR centers from three Swedish University Hospitals. The aim is to include 150 patients with MI < 75 years of age who are confident smartphone and/or Internet users. In addition to participation in CR programs according to the usual routine at each center, patients randomized to the intervention arm will receive access to the web-based app. A CR nurse reviews the patients' self-reported data twice weekly through a medical interface at the clinic. The primary outcome of the study will be change in submaximal exercise capacity (in watts) between 2 and 4 weeks after discharge and when the patient has completed his/her exercise program at the CR center, usually around 3-6 months post-discharge. Secondary outcomes include changes in self-reported physical activity, objectively assessed physical activity by accelerometry, self-rated health, dietary, and smoking habits, body mass index, blood pressure, blood lipids, and glucose/HbA1c levels between inclusion and follow-up visits during the first year post-MI. Additionally, we will assess uptake and adherence to the application, the number of CR staff contacts, and the incidence of cardiovascular events at 1 and 3 years after the MI. Patient recruitment started in 2016, and the first study results are expected in the beginning of 2019. Discussion: The present study will add evidence to whether electronic communication can be used to improve traditional CR programs for patients after MI. Trial registration: ClinicalTrials.gov, NCT03260582 . Retrospectively registered on 24 August 2017.
MeSH term(s)	Cardiac Rehabilitation/methods ; Communication ; Humans ; Life Style ; Multicenter Studies as Topic ; Myocardial Infarction/rehabilitation ; Outcome Assessment (Health Care) ; Prognosis ; Randomized Controlled Trials as Topic ; Research Design ; Risk Factors ; Sample Size ; Smartphone ; Telemedicine
Language	English
Publishing date	2019-01-24
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1468-6708
ISSN (online)	1745-6215 ; 1468-6694
ISSN	1468-6708
DOI	10.1186/s13063-018-3118-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population-based case-control study.

Hálfdánarson, Óskar Ö / Fall, Katja / Ogmundsdottir, Margret H / Lund, Sigrún H / Steingrímsson, Eiríkur / Ogmundsdottir, Helga M / Zoega, Helga

Pharmacoepidemiology and drug safety

2018 Volume 28, Issue 4, Page(s) 471–478

Abstract: Purpose: Increased expression of Vacuolar-type H: Methods: In this population-based ...

Abstract	Purpose: Increased expression of Vacuolar-type H Methods: In this population-based case-control study, we identified incident cases of breast cancer (n = 1739), prostate cancer (n = 1897), and malignant melanoma (n = 385) in Iceland between 2005 and 2014 from the Icelandic Cancer Registry. We assessed varying levels of PPI use through record linkages to the Icelandic Medicines Registry. For each case, we selected up to 10 age-matched, sex-matched, and calendar-matched population controls using risk-set sampling. Using conditional logistic regression, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) controlling for NSAID use. Results: Adjusted ORs associated with ever use of PPIs were 1.03 (95% CI: 0.92-1.16) for breast cancer, 1.12 (95% CI: 1.00-1.25) for prostate cancer, and 0.84 (95% CI: 0.69-1.12) for malignant melanoma. Analyses of high use of PPIs (≥1000 DDDs) yielded ORs of 0.97 (95% CI: 0.78-1.19), 1.20 (0.99-1.47), and 0.59 (0.40-1.13) for breast cancer, prostate cancer, and malignant melanoma, respectively. Analyses of cumulative exposure to PPIs did not support a dose-response relationship for any of the three cancer types. Conclusions: Our findings do not support a chemopreventive effect of PPI use on breast cancer, prostate cancer, or malignant melanoma.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/epidemiology ; Breast Neoplasms/prevention & control ; Case-Control Studies ; Female ; Humans ; Iceland/epidemiology ; Logistic Models ; Male ; Melanoma/epidemiology ; Melanoma/prevention & control ; Middle Aged ; Odds Ratio ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms/prevention & control ; Proton Pump Inhibitors/administration & dosage ; Registries/statistics & numerical data ; Risk Factors ; Skin Neoplasms/epidemiology ; Skin Neoplasms/prevention & control ; Tumor Microenvironment/drug effects ; Vacuolar Proton-Translocating ATPases/antagonists & inhibitors ; Vacuolar Proton-Translocating ATPases/metabolism ; Young Adult
Chemical Substances	Proton Pump Inhibitors ; Vacuolar Proton-Translocating ATPases (EC 3.6.1.-)
Language	English
Publishing date	2018-12-19
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1099748-9
ISSN	1099-1557 ; 1053-8569
ISSN (online)	1099-1557
ISSN	1053-8569
DOI	10.1002/pds.4702
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3395: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Proton-pump inhibitors among adults: a nationwide drug-utilization study.

Hálfdánarson, Óskar Ö / Pottegård, Anton / Björnsson, Einar S / Lund, Sigrún H / Ogmundsdottir, Margret H / Steingrímsson, Eiríkur / Ogmundsdottir, Helga M / Zoega, Helga

Therapeutic advances in gastroenterology

2018 Volume 11, Page(s) 1756284818777943

Abstract: Background: The use of proton-pump inhibitors (PPIs) has grown worldwide, and there are concerns about increased unsubstantiated long-term use. The aim of the study was to describe the real-world use of PPIs over the past decade in an entire national ... ...

Abstract	Background: The use of proton-pump inhibitors (PPIs) has grown worldwide, and there are concerns about increased unsubstantiated long-term use. The aim of the study was to describe the real-world use of PPIs over the past decade in an entire national population. Methods: This was a nationwide population-based drug-utilization study. Patterns of outpatient PPI use among adults in Iceland between 2003 and 2015 were investigated, including annual incidence and prevalence, duration of use, and dose of tablet used (lower Results: We observed 1,372,790 prescription fills over the entire study period, of which 95% were for higher-dose PPIs. Annual incidence remained stable across time (3.3-4.1 per 100 persons per year), while the annual prevalence increased from 8.5 per 100 persons to 15.5 per 100 persons. Prevalence increased with patient age and was higher among women than men. Duration of treatment increased with patients' age (36% of users over 80 years remained on treatment after 1 year compared with 13% of users aged 19-39 years), and was longer among those initiating on a higher dose compared with a lower dose. The proportion of PPI users concurrently using nonsteroidal anti-inflammatory drugs decreased over the study period, while the proportion concurrently using acetylsalicylic acid, oral anticoagulants, or platelet inhibitors increased. Conclusions: In this nationwide study, a considerable increase in overall outpatient use of PPIs over a 13-year period was observed, particularly among older adults. Patients were increasingly treated for longer durations than recommended by clinical guidelines and mainly with higher doses.
Language	English
Publishing date	2018-05-30
Publishing country	England
Document type	Journal Article
ZDB-ID	2440710-0
ISSN	1756-2848 ; 1756-283X
ISSN (online)	1756-2848
ISSN	1756-283X
DOI	10.1177/1756284818777943
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito